Table 5. The associations between mTOR rs2295080 polymorphism and clinical characteristics of breast cancer patients.
| Variables | TT (%) | GT (%) | P | OR (95% CI) | GG (%) | P | OR (95% CI) | GT + GG (%) | P | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Tumor size | ||||||||||
| < 2 cm | 179 (61.9) | 104 (35.9) | 6 (2.2) | 110 (38.1) | ||||||
| ≥ 2 cm | 172 (63.4) | 93 (34.3) | 0.365 | 0.83 (0.55–1.25) | 6 (2.3) | 0.428 | 0.82 (0.51–1.34) | 99 (36.6) | 0.33 | 0.82 (0.56–1.21) |
| LN metastasis | ||||||||||
| Negative | 92 (38.9) | 134 (56.8) | 10 (4.3) | 144 (61.1) | ||||||
| Positive | 259 (79.9) | 63 (19.4) | 0.005 | 0.55 (0.37–0.84) | 2 (0.7) | 0.001 | 0.65 (0.67–1.36) | 219 (20.1) | 0.003 | 0.56 (0.38–0.82) |
| ER | ||||||||||
| Negative | 160 (64.7) | 82 (33.2) | 5 (2.1) | 87 (35.3) | ||||||
| Positive | 191 (61.0) | 115 (36.7) | 0.43 | 0.85 (0.58–1.26) | 7 (2.3) | 0.334 | 0.80 (0.50–1.26) | 122 (39.0) | 0.40 | 0.85 (0.59–1.23) |
| PR | ||||||||||
| Negative | 153 (60.0) | 97 (38.0) | 5 (2.0) | 102 (40.0) | ||||||
| Positive | 198 (64.9) | 100 (32.8) | 0.909 | 0.98 (0.66–1.44) | 7 (2.3) | 0.143 | 0.71 (0.45–1.12) | 107 (35.1) | 0.48 | 0.89 (0.61–1.26) |
| Her-2 | ||||||||||
| Negative | 241 (61.9) | 140 (35.9) | 8 (2.2) | 148 (38.1) | ||||||
| Positive | 110 (64.3) | 57 (33.3) | 0.625 | 0.85 (0.55–1.25) | 4 (2.4) | 0.528 | 0.89 (0.61–1.37) | 61 (62.7) | 0.52 | 0.83 (0.63–1.31) |
LN, Axillary lymph node; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, human epidermal growth factor receptor 2.